Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)

Data on P-321 from clinical research to be presented on May 3rd

Durham, NC (May 2, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and epithelial diseases, announced today the presentation of a poster containing clinical data for the development stage dry eye treatment P-321. The presentation is a review of the results from a clinical trial of P-321 versus placebo in patients with dry eye disease and will be presented at the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington on May 3rd, 2016.

P-321 Poster Presentation:

- “Safety, Tolerability and Pharmacokinetics of P-321 Ophthalmic Solution in Subjects with Mild to Moderate Dry Eye Disease.” Poster Number 2875 - A0084 to be presented during Dry Eye II Session on May 3rd from 8:30 AM to 10:15 AM.

About ENaC and P-321

The epithelial sodium channel (ENaC) plays a key role in the regulation of tear film fluid and is therefore an attractive target for the treatment of dry eye. Studies with preclinical models of dry eye disease have demonstrated that by blocking ENaC, the tear film volume could be restored, maintaining its protective and lubricating actions on the ocular surface.

P-321 is the result of a comprehensive research effort to develop a potent ENaC inhibitor with unique pharmacokinetic and pharmacodynamics characteristics designed for topical ocular administration, metabolic stability and limited systemic exposure. Parion Sciences has completed a phase 1/2a clinical study in dry eye patients and is initiating additional Phase 2 studies in this indication.
About Parion Sciences

Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation Therapeutics, Inc. For more information, please see our website at www.Parion.com.